Developer docs
API playgroundTry for free, no card

Search company profiles

Heranova Lifesciences

Full company profile

uuid0000yml

Namestring
Heranova Lifesciences
Legal namestring
Heranova Lifesciences Inc.
Websiteurl
heranova.com
Company typeenum
Private
Founded yearint
2022
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersBurlington, United States
HQ citystring
Burlington
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
women's health diagnostics, endometriosis blood testing, reproductive medicine diagnostics, microRNA biomarker assays, fertility diagnostic services
Industry5 codes
PRIMARYHLAHAAAI
Genetic, Cytogenetic & Prenatal Screening IVD
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
SECONDARYHLAAALAJ
Prenatal, Newborn & Reproductive Diagnostics (NIPT, IVF/PGT, newborn screening)
SECONDARYHLAFAMAH
Genetic & Prenatal Testing Laboratories
SECONDARYHLAAALAD
Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics)
SECONDARYHLAGAJAD
Bioinformatics & Multi-omics Analysis Software
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
NAICS code2 codes
  • Medical Laboratories621511
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Services-Medical Laboratories8071
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
Women's Health Diagnostics
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Diagnostic Testing Services
TypeOne Time License
Description

HerAnova generates revenue through laboratory-developed diagnostic tests (LDTs). HerResolve is offered as a blood-based test for endometriosis detection, currently available at select IVF and reproductive medicine centers. Revenue is derived from test processing and analysis for healthcare providers and patients.

einpresswire.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 7 records shown
1HerResolve
Description

Non-invasive, LDT-validated blood-based diagnostic test for confirmation of endometriosis in symptomatic women.

heranova.com
+6 more records
Core offering1 text field

Heranova Lifesciences develops and commercializes non-invasive blood-based and microbiome-based diagnostic tests for endometriosis and female fertility, with the core product HerResolve™ integrating multi-omic biomarkers (microRNA, protein, hormone) with a proprietary random forest AI algorithm to confirm endometriosis without surgical laparoscopy. The company also has a development pipeline spanning diagnostic assays (HerEndo, HerBiota, HerTempo, HerReceptivity) and the HerCAPA biphasic in vitro maturation fertility technology platform.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • AUC of 0.944 (95% CI: 0.892-0.996) demonstrating excellent discriminatory power
+4 more records
Product overview1 text field

Heranova Lifesciences is a Boston-based biotech company offering integrated care solutions for women's health in endometriosis and female fertility. The core commercial product is HerResolve™, a non-invasive blood-based diagnostic test for endometriosis that uses multi-omic biomarker analysis (microRNA, protein, hormone) with machine learning algorithms. The product pipeline includes HerEndo™ (vaginal microbiome-based endometriosis screening), HerBiota™ and HerBiota™-Complete (uterine/vaginal microbiome tests), HerTempo™ (ovarian reserve assessment), HerReceptivity™ (endometrial receptivity test), and HerCAPA™ (hormone-free fertility technology). These diagnostic tests work together as an integrated suite to address the multifactorial nature of endometriosis and infertility.

Product and service7 records
1HerResolve™
CategoryEndometriosis Diagnostic Test
Description

Non-invasive, LDT-validated, blood-based test that confirms endometriosis in symptomatic women using a multi-omic assay integrating microRNA, protein, and hormone biomarkers analyzed through a proprietary machine learning algorithm. It is for symptomatic women of reproductive age and is ordered by physicians at IVF and reproductive medicine centers.

2HerEndo™
CategoryEndometriosis Screening Test
Description

Minimally invasive vaginal swab test providing comprehensive assessment of vaginal microbiome including bacterial and fungal composition and associated antibiotic resistance markers for endometriosis screening using qPCR and next-generation sequencing.

3HerBiota™
CategoryGynecological Microbiome Diagnostic
Description

NGS-based test to assess uterine microbiome environment for detecting chronic endometritis and other gynecological conditions due to pathogens and/or dysbiosis.

4HerBiota™-Complete
CategoryGynecological Microbiome Diagnostic
Description

NGS-based test assessing both uterine and vaginal microbiome environment to help clinicians provide personalized treatment recommendations for gynecological conditions.

5HerTempo™
CategoryFertility Diagnostic Test
Description

Proprietary algorithmic-based ovarian reserve assessment for estimating a woman's remaining childbearing years based on patient-specific clinical information.

6HerReceptivity™
CategoryIVF Endometrial Receptivity Test
Description

NGS-based test to identify each patient's optimal embryo transplantation time during the IVF process to address recurrent implantation failure.

7HerCAPA™
CategoryFertility Treatment Technology Platform
Description

Biphasic in vitro maturation (CAPA-IVM) technology platform for hormone-free assisted reproduction, designed to mature immature eggs with minimal or no conventional ovarian stimulation medications.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
1Lavima Fertility (Belgium)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

HerAnova is the exclusive partner of Lavima Fertility for development of HerCAPA biphasic in vitro maturation (CAPA-IVM) technology in Greater China. HerCAPA is designed to mature immature eggs with minimal hormonal stimulation, potentially reducing treatment burden for fertility patients.

heranova.com
2Sichuan Jinxin Xinan Women's and Children's Hospital (China)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Leading reproductive medicine center in China conducting clinical studies using HerCAPA technology. The hospital achieved the first healthy live birth using HerCAPA in May 2026, marking a landmark clinical translation achievement.

heranova.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Clinical site contributing to HerResolve multi-center validation study involving 298 reproductive-age women across US, Europe, and Hong Kong.

4Prince of Wales Hospital of Hong Kong
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Clinical site contributing to HerResolve multi-center validation study involving 298 reproductive-age women across US, Europe, and Hong Kong.

heranova.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Clinical site contributing to HerResolve multi-center validation study involving 298 reproductive-age women across US, Europe, and Hong Kong.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

DotLab is developing a blood-based microRNA diagnostic test for endometriosis, making it the most directly comparable competitor to Heranova's HerResolve product. Both companies target the same unmet need of non-invasive endometriosis detection using biomarker-based approaches.

TypeBroad incumbent
Description

CooperSurgical is a major provider of fertility and women's health products and services including IVF diagnostics and ART-related tools. It is comparable to Heranova because it serves the same IVF and reproductive medicine customer base with diagnostic and treatment solutions across the fertility journey.

TypeBroad incumbent
Description

Hologic is a large women's health diagnostics company with established products in reproductive health, prenatal screening, and gynecological conditions. Its scale, commercial reach, and FDA-cleared diagnostic portfolio represent both a competitive threat and a potential strategic acquirer for Heranova.

TypeDirect peer
Description

Natera is a molecular diagnostics company with a strong reproductive health franchise including preconception and prenatal testing. Its use of molecular biomarker technologies (including cell-free DNA) and its commercial footprint in IVF centers makes it a relevant comparable for Heranova's diagnostics pipeline.

TypeBroad incumbent
Description

Myriad Genetics operates a broad molecular diagnostics franchise with women's health products including hereditary cancer and prenatal screening. Its established payer relationships and clinical sales force make it a relevant adjacent comparable in the molecular diagnostics space.

TypeEmerging player
Description

Bio-Techne provides research and diagnostic tools including biomarker assay platforms and reproductive health research reagents. Its involvement in biomarker discovery and clinical assay development places it in the same technology category as Heranova's multi-omic diagnostic approach.

TypeBroad incumbent
Description

Roche is a global diagnostics and pharmaceutical leader with extensive women's health and reproductive medicine franchises. Penny Wan, Heranova's Chairwoman, is a former Roche executive, and Roche represents both a potential strategic partner and an established comparable in women's health diagnostics.

TypeBroad incumbent
Description

GE HealthCare provides women's health ultrasound and imaging solutions used in endometriosis evaluation and IVF workflows. Its current imaging dominance in the diagnostic pathway that HerResolve aims to disrupt makes it a key adjacent comparable and potential strategic partner.

TypeDirect peer
Description

Aspira Women's Health is a commercial-stage diagnostics company focused on women's health with products for ovarian cancer risk assessment. Its commercial diagnostic approach in a women's health specialty market is structurally similar to Heranova's HerResolve go-to-market model.

TypeEmerging player
Description

Ferring Pharmaceuticals is a leading reproductive medicine company focused on fertility treatments and obstetric products. Its deep IVF customer relationships and CSO Marcel van Duin's prior role make it a relevant strategic comparable in the fertility therapeutics space Heranova is entering with HerCAPA.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability6 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors7 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Heranova Lifesciences

Women's Health Diagnosticsheranova.com

Heranova Lifesciences firmographics

Firmographics
Name
Heranova Lifesciences
Legal name
Heranova Lifesciences Inc.
Website
https://heranova.com
Company type
Private
Founded year
2022
Operating status
Operating
Headcount range
11–50 employees
Ownership category
akta.pro rank

Heranova Lifesciences industry classification

Industry
Product category
Women's Health Diagnostics
NAICS
Medical Laboratories (621511), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAHAAAI
Genetic, Cytogenetic & Prenatal Screening IVD
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
SECONDARYHLAAALAJ
Prenatal, Newborn & Reproductive Diagnostics (NIPT, IVF/PGT, newborn screening)
SECONDARYHLAFAMAH
Genetic & Prenatal Testing Laboratories
SECONDARYHLAAALAD
Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics)
SECONDARYHLAGAJAD
Bioinformatics & Multi-omics Analysis Software
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)

Keywords

  • Women's health diagnostics
  • Endometriosis blood testing
  • Reproductive medicine diagnostics
  • MicroRNA biomarker assays
  • Fertility diagnostic services

Where Heranova Lifesciences is headquartered

Location

Headquarters

HQ city
Burlington
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Heranova Lifesciences business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Diagnostic Testing Services: HerAnova generates revenue through laboratory-developed diagnostic tests (LDTs). HerResolve is offered as a blood-based test for endometriosis detection, currently available at select IVF and reproductive medicine centers. Revenue is derived from test processing and analysis for healthcare providers and patients.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels7 records

Heranova Lifesciences product offering

Product offering

Core offering

Heranova Lifesciences develops and commercializes non-invasive blood-based and microbiome-based diagnostic tests for endometriosis and female fertility, with the core product HerResolve™ integrating multi-omic biomarkers (microRNA, protein, hormone) with a proprietary random forest AI algorithm to confirm endometriosis without surgical laparoscopy. The company also has a development pipeline spanning diagnostic assays (HerEndo, HerBiota, HerTempo, HerReceptivity) and the HerCAPA biphasic in vitro maturation fertility technology platform.

Product overview

Heranova Lifesciences is a Boston-based biotech company offering integrated care solutions for women's health in endometriosis and female fertility. The core commercial product is HerResolve™, a non-invasive blood-based diagnostic test for endometriosis that uses multi-omic biomarker analysis (microRNA, protein, hormone) with machine learning algorithms. The product pipeline includes HerEndo™ (vaginal microbiome-based endometriosis screening), HerBiota™ and HerBiota™-Complete (uterine/vaginal microbiome tests), HerTempo™ (ovarian reserve assessment), HerReceptivity™ (endometrial receptivity test), and HerCAPA™ (hormone-free fertility technology). These diagnostic tests work together as an integrated suite to address the multifactorial nature of endometriosis and infertility.

Differentiator

Problem solved

Functional benefit

Brands

  • HerResolve: Non-invasive, LDT-validated blood-based diagnostic test for confirmation of endometriosis in symptomatic women.
  • HerEndo
  • HerBiota
  • HerBiota-Complete
  • HerTempo
  • HerReceptivity
  • HerCAPA

Products and services

  • HerResolve™ Non-invasive, LDT-validated, blood-based test that confirms endometriosis in symptomatic women using a multi-omic assay integrating microRNA, protein, and hormone biomarkers analyzed through a proprietary machine learning algorithm. It is for symptomatic women of reproductive age and is ordered by physicians at IVF and reproductive medicine centers.
  • HerEndo™ Minimally invasive vaginal swab test providing comprehensive assessment of vaginal microbiome including bacterial and fungal composition and associated antibiotic resistance markers for endometriosis screening using qPCR and next-generation sequencing.
  • HerBiota™ NGS-based test to assess uterine microbiome environment for detecting chronic endometritis and other gynecological conditions due to pathogens and/or dysbiosis.
  • HerBiota™-Complete NGS-based test assessing both uterine and vaginal microbiome environment to help clinicians provide personalized treatment recommendations for gynecological conditions.
  • HerTempo™ Proprietary algorithmic-based ovarian reserve assessment for estimating a woman's remaining childbearing years based on patient-specific clinical information.
  • HerReceptivity™ NGS-based test to identify each patient's optimal embryo transplantation time during the IVF process to address recurrent implantation failure.
  • HerCAPA™ Biphasic in vitro maturation (CAPA-IVM) technology platform for hormone-free assisted reproduction, designed to mature immature eggs with minimal or no conventional ovarian stimulation medications.

Quantifiable outcome

  • AUC of 0.944 (95% CI: 0.892-0.996) demonstrating excellent discriminatory power
  • +4 more outcomes

Companies that use Heranova Lifesciences

Customer profile

Named customers4 records

Segments3 records

Ideal customer profiles1 record

Heranova Lifesciences technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability6 records

Feature4 records

Heranova Lifesciences partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core.

  • Lavima Fertility (Belgium)coreStrategic or Co-development PartnerHerAnova is the exclusive partner of Lavima Fertility for development of HerCAPA biphasic in vitro maturation (CAPA-IVM) technology in Greater China. HerCAPA is designed to mature immature eggs with minimal hormonal stimulation, potentially reducing treatment burden for fertility patients.
  • Sichuan Jinxin Xinan Women's and Children's Hospital (China)coreStrategic or Co-development PartnerLeading reproductive medicine center in China conducting clinical studies using HerCAPA technology. The hospital achieved the first healthy live birth using HerCAPA in May 2026, marking a landmark clinical translation achievement.
  • Johns Hopkins School of MedicinecoreStrategic or Co-development PartnerClinical site contributing to HerResolve multi-center validation study involving 298 reproductive-age women across US, Europe, and Hong Kong.
  • Prince of Wales Hospital of Hong KongcoreStrategic or Co-development PartnerClinical site contributing to HerResolve multi-center validation study involving 298 reproductive-age women across US, Europe, and Hong Kong.
  • Kaiser PermanentecoreStrategic or Co-development PartnerClinical site contributing to HerResolve multi-center validation study involving 298 reproductive-age women across US, Europe, and Hong Kong.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Heranova Lifesciences competitors and assessment

Company assessment

Direct peers

  • DotLab: DotLab is developing a blood-based microRNA diagnostic test for endometriosis, making it the most directly comparable competitor to Heranova's HerResolve product. Both companies target the same unmet need of non-invasive endometriosis detection using biomarker-based approaches.
  • Natera: Natera is a molecular diagnostics company with a strong reproductive health franchise including preconception and prenatal testing. Its use of molecular biomarker technologies (including cell-free DNA) and its commercial footprint in IVF centers makes it a relevant comparable for Heranova's diagnostics pipeline.
  • Aspira Women's Health: Aspira Women's Health is a commercial-stage diagnostics company focused on women's health with products for ovarian cancer risk assessment. Its commercial diagnostic approach in a women's health specialty market is structurally similar to Heranova's HerResolve go-to-market model.

Broad incumbents

  • CooperSurgical (CooperCompanies): CooperSurgical is a major provider of fertility and women's health products and services including IVF diagnostics and ART-related tools. It is comparable to Heranova because it serves the same IVF and reproductive medicine customer base with diagnostic and treatment solutions across the fertility journey.
  • Hologic: Hologic is a large women's health diagnostics company with established products in reproductive health, prenatal screening, and gynecological conditions. Its scale, commercial reach, and FDA-cleared diagnostic portfolio represent both a competitive threat and a potential strategic acquirer for Heranova.
  • Myriad Genetics: Myriad Genetics operates a broad molecular diagnostics franchise with women's health products including hereditary cancer and prenatal screening. Its established payer relationships and clinical sales force make it a relevant adjacent comparable in the molecular diagnostics space.
  • F. Hoffmann-La Roche: Roche is a global diagnostics and pharmaceutical leader with extensive women's health and reproductive medicine franchises. Penny Wan, Heranova's Chairwoman, is a former Roche executive, and Roche represents both a potential strategic partner and an established comparable in women's health diagnostics.
  • GE HealthCare: GE HealthCare provides women's health ultrasound and imaging solutions used in endometriosis evaluation and IVF workflows. Its current imaging dominance in the diagnostic pathway that HerResolve aims to disrupt makes it a key adjacent comparable and potential strategic partner.

Emerging players

  • Bio-Techne: Bio-Techne provides research and diagnostic tools including biomarker assay platforms and reproductive health research reagents. Its involvement in biomarker discovery and clinical assay development places it in the same technology category as Heranova's multi-omic diagnostic approach.
  • Ferring Pharmaceuticals: Ferring Pharmaceuticals is a leading reproductive medicine company focused on fertility treatments and obstetric products. Its deep IVF customer relationships and CSO Marcel van Duin's prior role make it a relevant strategic comparable in the fertility therapeutics space Heranova is entering with HerCAPA.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Heranova Lifesciences social profiles

Digital presence

Heranova Lifesciences compliance and trust

Trust signal

Compliance2 records

Heranova Lifesciences financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Heranova Lifesciences leadership team

Management profile

Number of profiles

Profiles7 records

Heranova Lifesciences funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Heranova Lifesciences M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Heranova Lifesciences

What does Heranova Lifesciences do?

Heranova Lifesciences develops and commercializes non-invasive blood-based and microbiome-based diagnostic tests for endometriosis and female fertility, with the core product HerResolve™ integrating multi-omic biomarkers (microRNA, protein, hormone) with a proprietary random forest AI algorithm to confirm endometriosis without surgical laparoscopy. The company also has a development pipeline spanning diagnostic assays (HerEndo, HerBiota, HerTempo, HerReceptivity) and the HerCAPA biphasic in vitro maturation fertility technology platform.

Is Heranova Lifesciences a public or private company?

Heranova Lifesciences is a private company. It is classified as venture growth investor backed and is currently operating.

When was Heranova Lifesciences founded?

Heranova Lifesciences was founded in 2022. It employs 11 to 50 people.

Where is Heranova Lifesciences based?

Heranova Lifesciences is headquartered in Burlington, United States, in the North America region.

How does Heranova Lifesciences make money?

One revenue line is on record: diagnostic Testing Services.

Who are Heranova Lifesciences's main competitors?

Direct peers on record are DotLab, Natera and Aspira Women's Health. Broad incumbents are CooperSurgical (CooperCompanies), Hologic, Myriad Genetics, F. Hoffmann-La Roche and GE HealthCare. Emerging players are Bio-Techne and Ferring Pharmaceuticals.

Does Heranova Lifesciences have an API?

No public API is recorded for Heranova Lifesciences.

What industry is Heranova Lifesciences in?

Heranova Lifesciences's product category is Women's Health Diagnostics. Its primary akta.pro industry code is HLAHAAAI, Genetic, Cytogenetic & Prenatal Screening IVD, with a secondary code of HLAAALAJ, Prenatal, Newborn & Reproductive Diagnostics (NIPT, IVF/PGT, newborn screening). Its NAICS code is 621511 and its SIC code is 8071.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Business & FinancialHeranovatm To Present Expanded Validation Data On Herresolvetm Endometriosis Blood Test At Global WebinarHerAnova Lifesciences will present expanded validation data for its HerResolve blood test at a global webinar on November 23-24, 2026. The study used 218 training samples and 277 validation samples, achieving an AUC of 0.95 and identifying 61.5% of endometriosis cases missed by imaging.EIN PresswireHerAnova™ Named Femtech Company of the Year at the Health Tech World Awards 2026HerAnova Lifesciences was named Femtech Company of the Year at the Health Tech World Awards 2026. Its HerResolve blood-based test for endometriosis showed 94% AUC, 80% sensitivity, and 97.5% specificity in a clinical study. The company aims to reduce diagnostic delays for women with endometriosis.EIN PresswireHerAnova™ Named Femtech Company of the Year at the Health Tech World Awards 2026HerAnova Lifesciences was named Femtech Company of the Year at the Health Tech World Awards 2026. Its HerResolve blood-based test for endometriosis showed 94% AUC, 80% sensitivity, and 97.5% specificity in a clinical study. The company aims to reduce diagnostic delays for women with endometriosis.EIN PresswireHerAnova™ Presents Real-World Data on HerResolve™ Endometriosis Blood Test at the 2026 Midwest Reproductive SymposiumHerAnova Lifesciences presented real-world data on its HerResolve blood test for endometriosis at the 2026 Midwest Reproductive Symposium. The analysis of 197 cases showed 53% detected and 47% not detected, with high-probability outputs aligning with detected classifications. The company plans to expand evidence for regulatory submission.EIN PresswireHerAnova Presents Clinical Validation Data on HerResolve™ Endometriosis Blood Test at the 2026 Endocrine Society MeetingHerAnova presented clinical validation data for HerResolve™, a blood-based endometriosis test, at the 2026 Endocrine Society Meeting. The study of 298 women showed an AUC of 0.944, 80% sensitivity, and 97.5% specificity, identifying 61.5% of cases missed by imaging. A prospective validation study is underway.HKTDCMedtech firm ramps up women’s health push in Hong KongHerAnova Lifesciences, a women's health medtech firm, is accelerating its development after opening its Hong Kong regional headquarters two years ago. The company focuses on endometriosis and infertility, with a certified endometriosis test and a pilot infertility treatment. It raised funding led by MindWorks Capital and the Hong Kong government's venture fund.EIN PresswireHerAnova™ Announces Late-Breaking Abstract Presentation at AGCES 2026 Annual MeetingHerAnova Lifesciences announced a late-breaking abstract presentation at AGCES 2026, highlighting its HerResolve blood test for endometriosis. The assay was validated against laparoscopic visualization with histology, and the company will exhibit at Booth #4. The test aims to reduce the seven-to-ten-year diagnostic delay.EIN PresswireHerAnova™ Commercializes HerResolve™ across a Growing Network of IVF Centers in the U.S.HerAnova Lifesciences has commercialized HerResolve, a non-invasive blood test for endometriosis, at IVF and reproductive medicine centers across the U.S. following completion of Laboratory Developed Test validation. The test is currently being used at Reproductive Partners Medical Group and CNY Fertility locations nationwide, and has demonstrated diagnostic accuracy comparable to surgical laparoscopy. The company plans to continue expanding access to additional reproductive medicine and gynecology practices while building clinical evidence.FinSMEsHeranova Lifesciences Raises $13.5M in Seed and Seed+ FundingHeranova Lifesciences, a biotech company focused on women's health, raised $13.5 million in Seed+ funding from investors including Pivotal bioVenture Partners China and Sinovation Ventures. The company plans to utilize the capital to launch non-invasive endometriosis tests and advance therapeutic programs for endometriosis and bacterial vaginosis.